ENVELOPE GENE VARIATION IN EQUINE INFECTIOUS ANEMIA VIRUS: IMPLICATIONS FOR VACCINE DEVELOPMENT

Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

ENVELOPE GENE VARIATION IN EQUINE INFECTIOUS ANEMIA VIRUS: IMPLICATIONS FOR VACCINE DEVELOPMENT

Vaccines 88. New Chemical and Genetic Approaches to Vaccination: Prevention of AIDS and Other Viral, Bacterial, and Parasitic Diseases. Ginsberg H et al, eds. New York, Cold Spring Harbor Laboratory, p. 297-302, 1988.. Unique Identifier : AIDSLINE ICDB/89649772
Payne SL; Ball JM; Issel CJ; Montelaro RC; Rushlow K; Dept. of Biochemistry, Louisiana State Univ., Baton Rouge, LA; 70803

Abstract: Equine infectious anemia virus (EIAV) is a member of the lentivirus subfamily of retroviruses, which also includes visna virus, caprine arthritis encephalitis virus, and the simian and human immunodeficiency viruses. The extent and nature of env gene variation among four antigenically distinct EIAV isolates were examined by nucleotide sequence analysis. Divergence in nucleotide and deduced amino acid sequences between pairs of virus isolates ranged from 0.6% to 3.4%. Although the outer envelope protein, gp90, displayed a greater degree of variation than the transmembrane protein, gp45, some highly conserved regions also occurred in gp90. Conserved epitopes in gp90 and gp45 have been defined and will be targeted for use in vaccine studies. The present data indicate that env gene amino acid substitution rates of less than 2% are sufficient to change the antigenic properties of EIAV. The degree and nature of env gene variation in EIAV are remarkably similar to that reported among HIV isolates recovered from a single patient, suggesting common mechanisms for env gene variation among lentiviruses. (7 Refs)

Keywords: Amino Acid Sequence Animal Base Sequence Epitopes/IMMUNOLOGY Equine Infectious Anemia/*IMMUNOLOGY *Genes, Viral Glycoproteins/IMMUNOLOGY Horses Infectious Anemia Virus, Equine/*GENETICS/IMMUNOLOGY Molecular Sequence Data Vaccines, Synthetic/*IMMUNOLOGY *Variation (Genetics) Viral Envelope Proteins/*GENETICS/IMMUNOLOGY Viral Vaccines/*IMMUNOLOGY MEETING PAPER

890330
M8930528

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .